Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitex Inactine Surgery Study On Schedule Despite Suspension Of Chronic Trial

This article was originally published in The Gray Sheet

Executive Summary

Vitex expects to complete a Phase III trial of its Inactine pathogen inactivation system for red blood cells used during surgery by 2005, even though the firm has halted a separate Phase III study in chronic transfusions

You may also be interested in...



Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex

Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells

Vitex conserves

Spending cuts include 50% workforce reduction, effective Nov. 21, following recent suspension of Phase III trial of the Inactine pathogen inactivation system for chronic red blood cell transfusions (1"The Gray Sheet" Nov. 24, 2003, p. 28). "Our goal is to reduce our burn rate by approximately 50% from its previous level to approximately $3 mil. per quarter," CEO John Barr explains. With about $5.5 mil. in cash on hand, the firm is evaluating "further spending reductions" and additional financing to continue a separate Phase III trial for acute transfusions during surgery...

Vitex conserves

Spending cuts include 50% workforce reduction, effective Nov. 21, following recent suspension of Phase III trial of the Inactine pathogen inactivation system for chronic red blood cell transfusions (1"The Gray Sheet" Nov. 24, 2003, p. 28). "Our goal is to reduce our burn rate by approximately 50% from its previous level to approximately $3 mil. per quarter," CEO John Barr explains. With about $5.5 mil. in cash on hand, the firm is evaluating "further spending reductions" and additional financing to continue a separate Phase III trial for acute transfusions during surgery...

Related Content

UsernamePublicRestriction

Register

MT019382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel